Next Article in Journal
Lipidomic Signatures Reveal Seasonal Shifts on the Relative Abundance of High-Valued Lipids from the Brown Algae Fucus vesiculosus
Next Article in Special Issue
Natural Products from Marine Fungi
Previous Article in Journal
Synthesis and Preliminary Biological Evaluation of Two Fluoroolefin Analogs of Largazole Inspired by the Structural Similarity of the Side Chain Unit in Psammaplin A
Previous Article in Special Issue
New Diketopiperazines from a Marine-Derived Fungus Strain Aspergillus versicolor MF180151
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Anthraquinone Derivatives from a Marine-Derived Fungus Sporendonema casei HDN16-802

1
Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China
2
Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science and Technology, Qingdao 266237, China
3
Key Laboratory of Testing and Evaluation for Aquatic Product Safety and Quality, Ministry of Agriculture and Rural Affairs, Yellow Sea Fisheries Research Institute, Chinese Academy of Fishery Sciences, Qingdao 266071, China
*
Author to whom correspondence should be addressed.
Mar. Drugs 2019, 17(6), 334; https://doi.org/10.3390/md17060334
Submission received: 30 April 2019 / Revised: 28 May 2019 / Accepted: 29 May 2019 / Published: 4 June 2019
(This article belongs to the Special Issue Natural Products from Marine Fungi)

Abstract

:
Five new anthraquinone derivatives, auxarthrols D–H (15), along with two known analogues (67), were obtained from the culture of the marine-derived fungus Sporendonema casei. Their structures, including absolute configurations, were established on the basis of NMR, HRESIMS, and circular dichroism (CD) spectroscopic techniques. Among them, compound 4 represents the second isolated anthraquinone derivative with a chlorine atom, which, with compound 6, are the first reported anthraquinone derivatives with anticoagulant activity. Compounds 1 and 3 showed cytotoxic activities with IC50 values from 4.5 μM to 22.9 μM, while compounds 1, 34, and 67 showed promising antibacterial activities with MIC values from 12.5 μM to 200 μM. In addition, compound 7 was discovered to display potential antitubercular activity for the first time.

Graphical Abstract

1. Introduction

Anthraquinones and their derivatives are a group of pigmented polyketides widely produced by fungi. Apart from their bright color attributed to the typical conjugate system in their structure, they have also attracted the attention of scientists due to their diversity of structures and wide range of pharmacological effects, such as their anti-infective, anti-inflammatory, and α-glucosidase inhibitory activities and cytotoxicity against cancer cells [1,2]. Following the discovery of altersolanol A reported in 1967 [3], a series of anthraquinone derivatives have been discovered from various fungal genera, including Alternaria [4,5], Streptomyces [6,7], Dactylaria [8], Bostryconema [9], Stemphylium [10], Pleospora [11], Auxarthron [12], Ampelomyces [13], Nigrospora [14], and Phomopsis [15].
During our exploration of novel bioactive secondary metabolites obtained from marine-derived microorganisms, a fungus Sporendonema casei HDN16-802 isolated from a sediment sample collected from Zhangzi Island was selected due to its special morphological characteristic (orange color) and tremendous metabolic profile identified via HPLC-UV. Further chemical study generated five new anthraquinones, named auxarthrols D–H (15), along with two known analogues (67). To the best of our knowledge, this is the first time that anthraquinone derivatives have been isolated from the fungus S. casei. The cytotoxicity, antibacterial, anticoagulant, and antitubercular activities of 17 were tested. Herein, we will describe the isolation, structural elucidation, and biological activities of the isolated compounds.

2. Results and Discussion

Sporendonema casei HDN16-802 was cultured (45 L) under static conditions with oatmeal medium at room temperature for one month. The fermentation product (mycelium and broth) was extracted with ethyl acetate to provide the crude extract (10 g). The crude extract was fractionated by different kinds of chromatography, including silica gel vacuum liquid chromatography (VLC), C-18 column chromatography (ODS), Sephadex LH-20 column chromatography, medium performance liquid chromatography (MPLC), and finally HPLC to yield 1 (10.0 mg), 2 (2.1 mg), 3 (5.1 mg), 4 (5.0 mg), 5 (4.5 mg), 6 (10.1 mg), and 7 (5.0 mg) (Figure 1).
Compound 1 was isolated as a pale yellow solid with the molecular formula C16H18O8, which was established on the basis of the (+)–HRESIMS ion peak at m/z 339.1076 [M+H]+ and m/z 361.0897 [M+Na]+, indicating eight degrees of unsaturation. The 1D NMR (1H-NMR, 13C NMR, and DEPT) spectrum (Table 1 and Table 2 and Supplementary Materials), together with HSQC correlations (Figure S5), provided five hydroxyl protons, including a chelated hydroxyl at δH 12.44 (s); two methyls, including one methoxy (δH 3.87, s; δC 56.7); one methylene (δH, 1.86, m; δC 34.2); five methines, including two meta-coupled aromatic sp2 methines [δH 6.79, d (2.4), δC 106.1; δH 6.83, d (2.4), δC 105.0] and two sp3 oxygenated methines [δH 3.61, dd (5.7, 3.1), δC 73.7; δH 4.22, dd (4.5, 3.1), δC 71.3]; and eight non-protonated carbons, including two conjugated ketones (δC 197.3 and 200.1), four aromatic carbons (δC 166.1, 166.3, 110.1, and 137.6), and two oxygenated quaternary (δC 72.3 and 78.2) carbons. A careful comparison of the above signals with those of the known compound auxarthrol B [12] revealed a very similar hydroanthraquinone skeleton, while the most significant differences were the absence of a hydroxyl group and the appearance of a methine signal [δH 3.36, m; δC 48.0] attributed to C-1a (Table 2). The key HMBC correlations from H-1a to C-9 and C-2 (Figure 2 and Supplementary Materials) further confirmed the planar structure of 1.
The relative configuration of the stereogenic carbons in 1 was detected by NOESY correlations and conformational analysis (Figure 3 and Figure S7). The NOESY correlations from H-3 to H-1a and 4a-OH, from H-1a to H-4, and from H-4 to 4a-OH indicated that H-1a and 4a-OH were located on the same face of the molecule, which meant that the B ring and C ring were cis fused. The NOESY correlations from H-1a and H-4 to H3-12 oriented H3-12 to the same side as H-1a and H-4. Computational simulation by Chemdraw (Minimize Energy program), together with the small J coupling constant between H-3 and H-4 (3JH-3, H-4 = 3.1 Hz), further confirmed the chair-chair conformation for rings B and C, where H-1a (ax), H-3 (eq), H-4 (ax), 4a-OH (eq), and H3-12 (ax) were oriented on the same face, thus completing the relative configuration of the stereogenic carbons in 1 (Figure 3). To determine the absolute configuration of compound 1, the theoretical calculated electronic circular dichroism (ECD) spectra of possible models were performed using TDDFT. The optimized conformation of the model was obtained and further used for the ECD calculation at the B3LYP/6-31+G(d) level. The pattern (2S, 3R, 4S, 1aR, 4aS)-1 of the calculated ECD spectrum was in reasonable agreement with the experimental ECD spectra (Figure 4). Thus, the absolute configuration of 1 was established as 2S, 3R, 4S, 1aR, 4aS, and we named it auxarthrol D.
Compound 2 was obtained as a pale yellow powder. Its molecular formula of C16H20O9 with seven degrees of unsaturation was determined by the ion peak m/z 341.1237 [M+H]+ in the (+)−HRESIMS. The molecular formula was also corroborated by exploiting 1H and 13C NMR spectroscopic data (Table 1 and Table 2 and Supplementary Materials). A comparison of these data with 1 revealed the same skeleton with different substitutions. The upfield shift of C-9 (δC 69.0 Vs. δC 197.3) and the downfield shift of C-1a (δC 79.3 Vs. δC 48.0) indicated that both of the C-9 and C-1a positions were substituted by a hydroxyl group in 2 (Table 2). Key HMBC correlations from H-9 to C-9, C-8, and C-1; from 1a-OH to C-1a and C-1; and from 9-OH to C-9 and C-9a (Figure 2 and Supplementary Materials) confirmed the locations of C-9 and C-1a hydroxyl groups, thus completing the planar structure of 2. The relative configurations of the stereogenic carbons were determined by NOESY correlations and J coupling constant analysis (Table 1, Figure 3 and Supplementary Materials). The NOESY correlations from H-4 to both 1a-OH and 4a-OH and from H-3 to 4a-OH, together with the small J coupling constant between H-3 and H-4 (3JH-3, H-4 = 3.0 Hz), indicated that 1a-OH, 4a-OH, H-3, and H-4 were located on the same face. Other NOE correlations from H-3 to H3-12 and 2-OH and from H-4 to 2-OH with the above evidence suggested a chair conformation of the C ring, where H-3 (eq), H-4 (ax), and 2-OH (ax) were on the same face, while H3-12 (eq) was oriented on the opposite face of the molecule. This conformation was further confirmed by using Chemdraw Minimize Energy simulation. Further NOESY correlation from H-9 to 4a-OH indicated that H-9 was on the same face as 4a-OH (Figure 3), thus providing the relative configuration of the stereogenic carbons of 2. The absolute configuration of 2 was determined by comparing the experimental and calculated ECD spectrum using time-dependent density-functional theory (TDDFT). The good agreement of the calculated ECD spectrum of (2R, 3R, 4S, 9S, 1aR, 4aR)-2 with that of the experimental spectrum (Figure 4) suggested that the absolute configuration of 2 was 2R, 3R, 4S, 9S, 1aR, 4aR, and we named it auxarthrol E.
Compound 3 was obtained as a pale yellow powder. The molecular formula of 3 was deduced as C16H20O9 (seven degrees of unsaturation) by (+)–HRESIMS m/z 357.1187 [M+H]+, which was also corroborated by 1H and 13C NMR spectroscopic data, as shown in Table 1 and Table 2, which was 16 amu more than the molecular mass of compound 2, therefore revealing a close relationship between 3 and 2. According to 1D NMR spectra, the presence of a methine signal at 2.87 ppm and the absence of a hydroxy group in 3 along with the upfield shift of C-4a (δC 53.3 Vs. δC 78.1) suggested that the 4a-OH in 2 was replaced by a hydrogen atom in 3 (Table 1 and Table 2), which was confirmed by the key HMBC correlation from H-4a to C-10 and C-4 (Figure 2 and Supplementary Materials). The relative configurations of the stereogenic carbons were also determined by NOESY correlations and J coupling constant analysis. The NOESY correlations from H-9 to H-4a and the large J coupling constant between H-4 and H-4a (3JH-4, H-4a = 9.7 Hz) indicated that H-4 (ax) and 1a-OH (ax) were on the same face, while H-4a (ax) was located on the opposite face, indicating that the B ring and C ring were trans fused. By using the Minimize Energy simulation programe in Chemdraw, both B and C rings were proposed to adopt a chair conformation, which provided the lowest steric energy. The NOESY correlation from H-4 to H3-12 with the small J coupling constant between H-3 and H-4 (3JH-3, H-4 = 3.0 Hz) assigned H3-12 and H-3 (eq) on the same face as H-4 (ax) (Figure 3), thus providing the relative configuration of the stereogenic carbons of 3. The good agreement of the calculated ECD spectrum of (2S, 3R, 4R, 9R, 1aS, 4aR)-3 with that of the experimental spectrum (Figure 5) suggested that the absolute configuration of 3 was 2S, 3R, 4R, 9R, 1aS, 4aR, and we named it auxarthrol F.
Compound 4 was obtained as a pale yellow powder. Its molecular formula of C16H18ClO8 (eight degrees of unsaturation) was determined by (+)–HRESIMS. The molecular formula was also corroborated by 1H and 13C NMR spectroscopic data (Table 1 and Table 2), suggesting that the structure of 4 resembled that of paradictyoarthrin A (8) [16], except for the absence of the hydroxyl group on C-9 and the presence of a keto-carbonyl signal at δC 190.6, indicating that the C-9 hydroxyl was replaced by a ketone. Further 2D NMR data confirmed the planar structure of 4 (Figure 2 and Supplementary Materials). The relative configurations of the stereogenic carbons of 4 were established by NOESY correlations and J coupling constant analysis (Table 1, Figure 3 and Supplementary Materials). The NOESY correlations from H-4 and H-3 to 1a-OH indicated that 1a-OH and 4a-Cl were located on the opposite side of the B ring, while the NOESY correlation from H-4 to H3-12 with a very small J coupling constant between H-3 and H-4 suggested that H-3 (eq), H-4 (ax), H3-12 (ax), and 1a-OH (ax) were oriented on the same side of the C ring. Moreover, the calculated ECD spectrum of the model compound (2S, 3R, 4S, 1aR, 4aS)-4 was well-matched with the experimental ECD spectrum of 4 (Figure 5), thus confirming the absolute structure of 4, and we named it auxarthrol G.
Compound 5 was obtained as a pale yellow solid, with the molecular formula C16H18O8 (eight degrees of unsaturation) from (+)–HRESIMS m/z 357.1187 [M+H]+ combined with 1H and 13C NMR spectroscopic data (Table 1 and Table 2). A comparison of 1D NMR data with those reported for altersolanol O [17] revealed a similar hydroanthraquinone skeleton, while the only differences were the absence of C-1 hydroxy and the replacement of the C-9 carbonyl group with a C-9 hydroxyl group in 5, which was further confirmed by the key HMBC correlations from H-9 to C-1a and C-9a, and from H2-1 to C-1a and C-9 (Figure 2 and Supplementary Materials). The relative configuration was also determined by NOESY correlations and J coupling constant analysis. The NOESY correlations from H-9 to H3-12 and H2-1 indicated that H-9 (ax) and H3-12 (ax) were on the same face, showing that the B ring and C ring were cis fused with the C-1a and C-4a epoxide ring on the opposite side to H-9 (Figure 3). Further NOESY correlations from H-4 to 2-CH3 with the small J coupling constant between H-3 and H-4 (3JH-3, H-4 = 3.7 Hz) suggested that H-3 (eq), H-4 (ax), and H3-12 (ax) were on the same face of the C ring. The absolute configurations of the stereogenic carbons of 5 were determined as 2S, 3R, 4S, 1aS, 4aS, 9S by a comparison of the experimental and calculated ECD spectra (Figure 6). Compound 5 was named auxarthrol H.
By a comparison of the NMR and MS data with the literature, two known compounds were identified as 4-dehydroxyaltersolanol A (6) [14] and altersolanol B (7) [11] (Figure 1).
As a typical class of anthraquinone derivatives, auxarthrols characterized with multiple hydroxyl groups attached on the hydroanthraquinone skeleton were first isolated in 1969 [11] and this was followed by total synthesis and biosynthetic studies [18,19]. By the end of 2018, seventeen altersolanols [19] and three auxarthrols [12,19] had been discovered and because of their broad range of biological activities [20,21,22], this class of compounds has received growing attention from the natural product community.
Compounds 17 were tested for their cytotoxic activity against eleven types of human cancer cell lines using SRB staining [23] and MTT [24] methods, with doxorubicin hydrochloride (Dox) as a positive control. Compounds 1 and 3 showed moderate cytotoxic activity against eleven human cancer cell lines, with IC50 values ranging from 4.5 μM to 22.9 μM (Table 3). The antimicrobial activity of 17 was also evaluated and 1, 3–4, and 6−7 showed promising antibacterial activity, with MIC values ranging from 12.5 μM to 200 μM. (Table 4).
Moreover, all the compounds were investigated for their anticoagulant activity using argatroban as a positive control (inhibition ratio: 65.0%). Compounds 4 and 6 displayed a moderate effect with an inhibition ratio of 47.8% and 51.5%, respectively (Table 5). In addition, all the compounds were tested for antitubercular activity, but only 7 displayed a weak antitubercular effect, with an MIC value of 20.0 μg/mL (Table 6).

3. Materials and Methods

3.1. General Experimental Procedures

UV spectra were recorded on Waters 2487. IR spectra were recorded on a Nicolet NEXUS 470 spectrophotometer in KBr discs (Thermo Scientific, Beijing, China). Optical rotations were measured on a JASCO P-1020 digital polarimeter (JASCO Corporation, Tokyo, Japan). HRESIMS and ESIMS data were obtained on a Thermo Scientific LTQ Orbitrap XL mass spectrometer. ECD spectra were measured on a JASCO J-715 spectra polarimeter (JASCO Corporation, Tokyo, Japan). NMR spectra were recorded on an Agilent 500 MHz DD2 spectrometer using TMS as the internal standard, and the chemical shifts were recorded as δ values. Semi-preparative HPLC was performed on an ODS column (HPLC (YMC-Pack ODS-A, 10 × 250 mm, 5 μm, 3 mL/min)). MPLC was performed on a Bona-Agela CHEETAHTM HP100 (Beijing Agela Technologies Co., Ltd., Beijing, China). Column chromatography (CC) was performed with silica gel (200–300 mesh, Qingdao Marine Chemical Inc. Qingdao, China) and Sephadex LH-20 (Amersham Biosciences, San Francisco, CA, USA), respectively.

3.2. Fungal Material

The fungal strain HDN16-802 was isolated from the sediment sample of Zhangzi Island, collected from Dalian, Liaoning Province, China. The strain was identified as Sporendonema casei based on sequencing of the ITS region (GenBank: MK578184). A voucher specimen strain was prepared on potato dextrose agar slants and deposited at −20 °C in the Key Laboratory of Marine Drugs, Chinese Ministry of Education.

3.3. Fermentation and Extraction

S. casei HDN16-802 was cultured on slants with PDA at 28 °C for 7 days. Further fermentation was carried out under static conditions at room temperature for 30 days in Erlenmeyer flasks (1000 mL), with each containing 53 g of oatmeal and naturally collected seawater (125 mL per flask) from Huiquan Bay, Qingdao, China. The pooled fermentation broth, together with mycelium (total of 45 L), were macerated and extracted with an equal volume of EtOAc three times. The organic layers were combined together and concentrated under reduced pressure to yield the extract (10 g).

3.4. Isolation

The extract (10 g) was fractionated by VLC column chromatography on silica gel using stepwise gradient elution with petroleum ether-CH2Cl2-MeOH (from PE only to PE with DCM in different ratios and DCM only later, and then from DCM only to DCM with MeOH in different ratios and MeOH only, depending on the polarity from small to large) to give six fractions (fraction 1 to fraction 6). Fraction 5 (eluted with 92:8 DCM-MeOH) was further separated by MPLC and then HPLC, eluting with MeOH/H2O (35:65) to obtain 1 (tR 28 min; 10.0 mg). Fraction 2 (eluted with 98:2 DCM-MeOH) was applied on a Sephadex LH-20 column and eluted with MeOH to provide six fractions (fraction 2-1 to fraction 2-6). Fraction 2-4 was separated by HPLC eluting with MeCN/H2O (23:77) to obtain 4 (tR 40 min; 5.0 mg) and 7 (tR 35 min; 5.0 mg). Fraction 3 (eluted with 94:6 DCM-MeOH) was further separated by a C-18 ODS column with a step gradient elution of MeOH-H2O (15:85-80:20), resulting in four fractions (fraction 3-1 to fraction 3-4). Fraction 3-1 was separated by HPLC eluting with MeCN/H2O (gradient 15:85-25:75) to provide 2 (tR 23 min; 2.1 mg), 3 (tR 25 min; 5.1 mg), 5 (tR 45 min; 4.5 mg), and 6 (tR 50 min; 10.1 mg) and Fraction 3-1-3 was further purified by HPLC using MeOH/H2O (24:76) as an eluent to obtain 5 (tR 25 min; 7.9 mg).
Auxarthrol D (1): Pale yellow crystal; [α] D 25 −20.45 (c 0.03, MeOH); UV (MeOH) λmax (log ε) 248 (2.4), 295 (1.2), 350 (1.2) nm; CD (2.5 mM, MeOH) λmax (Δε) 218 (+0.74), 240 (−1.78) nm, 260 (+3.13)nm, 333 (−3.68) nm; IR (KBr) νmax 3366, 2940, 2360, 1700, 1636, 1615, 1385, 1305, 1204, 1164, 1102, 1032, 910 cm−1; for 1H and 13C NMR data, see Table 1 and Table 2; HRESIMS m/z 339.1076 [M+H]+ (calculated for C16H19O8, 339.1074)
Auxarthrol E (2): Pale yellow powder; [α] D 25 −19.0 (c 0.04, MeOH); UV (MeOH) λmax (log ε) 290 (2.4), 330 (1.6) nm; CD (2.5 mM, MeOH) λmax (Δε) 218 (−1.74), 240 (+0.58) nm, 300 (+3.78) nm; IR (KBr) νmax 3356, 2934, 2361, 1717, 1625, 1577, 1376, 1291, 1204, 1158, 1074, 851 cm−1; for 1H and 13C NMR data, see Table 1 and Table 2; HRESIMS m/z 357.1187 [M+H]+ (calculated for C16H21O9, 357.1180).
Auxarthrol F (3): Pale yellow powder; [α] D 25 −65.0 (c 0.2, MeOH); UV (MeOH) λmax (log ε) 280 (2.4), 340 (1.0) nm; CD (2.5 mM, MeOH) λmax (Δε) 218 (−1.54) nm, 240 (+0.78) nm, 300 (+3.12) nm; IR (KBr) νmax 3379, 2925, 2362, 1626, 1375, 1296, 1204, 1160, 1084, 1032, 849, 780 cm−1; for 1H and 13C NMR data, see Table 1 and Table 2; HRESIMS m/z 341.1237 [M+H]+ (calculated for C16H21O8, 347.1231).
Auxarthrol G (4): Pale yellow powder; [α] D 25 +5.38 (c 0.08, MeOH); UV (MeOH) λmax (log ε) 245 (2.4), 300 (1.0), 350 (1.2) nm; CD (2.5 mM, MeOH) λmax (Δε) 210 (+3.74), 267 (−1.78), 333 (2.73) nm; IR(KBr) νmax 3375, 2924, 2359, 1636, 1615, 1385, 1296, 1205, 1162, 1030, 771 cm−1; for 1H and 13C NMR data, see Table 1 and Table 2; HRESIMS m/z 373.0685 [M+H]+ (calculated for C16H16O8Cl, 373.0685).
Auxarthrol H (5): Pale yellow powder; [α] D 25 +12.17 (c 0.2, MeOH); UV (MeOH) λmax (log ε)274 (2.4), 315 (1.4) nm; CD (2.5 mM, MeOH) λmax (Δε) 218 (−1.74), 242 (+0.78) nm, 290 (+2.56) nm, 315 (−1.24) nm, 356 (+0.54) nm; IR (KBr) νmax 3356, 2933, 2361, 1627, 1376, 1298, 1205, 1159, 1103, 1024, 950, 601 cm−1; for 1H and 13C NMR data, see Table 1 and Table 2; HRESIMS m/z 339.1080 [M+H]+ (calculated for C16H19O8, 339.1074).

3.5. Assay of Cytotoxic Activity

Cytotoxic activity was evaluated as previously reported [25].

3.6. Assay of Antimicrobial Activity

Antimicrobial activity was evaluated as previously reported [26].

3.7. Assay of Anticoagulant Activity

Anticoagulant activity was evaluated as previously reported [27].

3.8. Assay of Antitubercular Activity

Antitubercular activity was evaluated as previously reported [28].

4. Conclusions

In conclusion, we reported the isolation and structural elucidation of five new bioactive anthraquinone derivatives (15), together with two known analogues (67), from Sporendonema casei. Compound 4 is the second anthraquinone derivative with a chlorine atom. Compounds 17 were evaluated for their cytotoxic, antimicrobial, anticoagulant, and antitubercular activity. Compounds 1 and 3 showed cytotoxic activities against eleven human cancer cell lines, with IC50 values ranging from 4.5 μM to 22.9 μM, while 1, 34, and 67 showed promising antibacterial activity, with MIC values ranging from 12.5 μM to 200 μM. Compounds 4 and 6 displayed a moderate anticoagulant effect, which are the first anthraquinone derivatives with this activity. In addition, 7 was found to display potential antitubercular activity.

Supplementary Materials

The following are available online at https://www.mdpi.com/1660-3397/17/6/334/s1, 1D and 2D NMR and HRESIMS spectra of 17. Figures S1–S8: 1D and 2D NMR and HRESIMS spectra of Auxarthrol D (1); Figures S9–S17: 1D and 2D NMR and HRESIMS spectra of Auxarthrol E (2); Figures S18–S25: 1D and 2D NMR and HRESIMS spectra of Auxarthrol F (3); Figures S26–S33: 1D and 2D NMR and HRESIMS spectra of Auxarthrol G (4); Figures S34–S41: 1D and 2D NMR and HRESIMS spectra of Auxarthrol H (5).

Author Contributions

The contributions of the respective authors are as follows: X.G. drafted the work and performed the fermentation and extraction, as well as the isolation. X.G. and C.S. elucidated the constituents. Y.F. and L.W. were involved in the biological evaluations. J.P., Q.C., Q.G., T.Z., and D.L. contributed to checking and confirming all of the procedures of the isolation and identification. G.Z. designed the study, supervised the laboratory work, and contributed to the critical reading of the manuscript, and was also involved in structural determination and bioactivity elucidation. All the authors have read the final manuscript and approved the submission.

Funding

This work was financially supported by the National Natural Science Foundation of China (41806167, 41606166), the Marine S&T Fund of Shandong Province for the Pilot National Laboratory for Marine Science and Technology (Qingdao) (No. 2018SDKJ0401-2), the Fundamental Research Funds for the Central Universities (201941001), and the Taishan Scholar Youth Expert Program in Shandong Province (tsqn201812021).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Zhou, Y.X.; Xia, W.; Yue, W.; Peng, C.; Rahman, K.; Zhang, H.; Evid, J. Rhein: A Review of Pharmacological Activities. Based Complement. Alternat. Med. 2015, 1–10. [Google Scholar] [CrossRef] [PubMed]
  2. Abu, N.; Ali, N.; Ho, W.; Yeap, S.; Aziz, M.Y.; Alitheen, N. Damnacanthal: A Promising Compound as a Medicinal Anthraquinone. Anticancer Agents Med. Chem. 2014, 14, 750–755. [Google Scholar] [CrossRef] [PubMed]
  3. Zheng, C.J.; Shao, C.L.; Guo, Z.Y.; Chen, J.F.; Deng, D.S.; Yang, K.L.; Chen, Y.Y.; Fu, X.M.; She, Z.G.; Lin, Y.C.; Wang, C.Y. Bioactive hydroanthraquinones and anthraquinone dimers from a soft coral-derived Alternaria sp. fungus. J. Nat. Prod. 2012, 75, 189–197. [Google Scholar] [CrossRef] [PubMed]
  4. Kanamaru, S.; Honma, M.; Murakami, T.; Tsushima, T.; Kudo, S.; Tanaka, K.; Nihei, K.; Nehira, T.; Hashimoto, M. Absolute stereochemistry of altersolanol A and alterporriols. Chirality. 2012, 24, 137–146. [Google Scholar] [CrossRef] [PubMed]
  5. Suemitsu, R.; Kitagawa, N.; Horie, S.; Kazawa, K.; Harada, T. Isolation and Identification of Altersolanol B (7-Methoxy-2-methyl-(2R, 3S)-1, 2, 3, 4-tetrahydro-2, 3, 5-trihydroxyanthraquinone) from the Mycelium of Alternaría porri (Ellis) Ciferri. Agric. Biol. Chem. 2014, 42, 1801–1802. [Google Scholar] [CrossRef]
  6. Kasai, M.; Shirahata, K.; Ishii, S.; Mineura, K.; Marumo, H.; Tanaka, H.; OMURA, S. Structure of Nanaomycin E, A New Naaomycin. J. Antibiot. 1979, 5, 442–445. [Google Scholar] [CrossRef]
  7. Okabe, T.; Nomoto, K.; Tanaka, N. Lactoquinomycin B, A Novel Antibiotic. J Antibiot. 1986, 1, 1–5. [Google Scholar] [CrossRef]
  8. Becker, A.M.; Rickards, R.W.; Schmalzl, K.J.; Yick, H.C. Metabolites of Dactylaria Lutea, the Structures of Dactylariol and the Antiprotozoal Antibiotic Dactylarin. J. Antibiot. 1978, 4, 324–329. [Google Scholar] [CrossRef]
  9. Noda, T.; Take, T.; Watanabe, T.; Abe, J. The Structure of Bostrycin. Tetrahedron 1970, 26, 1339–1346. [Google Scholar] [CrossRef]
  10. Debbab, A.; Aly, A.H.; Edrada-Ebel, R.A.; Wray, V.; Müller, W.E.G.; Totzke, F.; Zirrgiebel, U.; Schächtele, C.; Kubbutat, M.H.G.; Lin, W.H.; et al. Bioactive Metabolites from the Endophytic Fungus Stemphylium globuliferum Isolated from Mentha pulegium. J. Nat. Prod. 2009, 72, 626–631. [Google Scholar] [CrossRef]
  11. Ge, H.M.; Song, Y.C.; Shan, C.Y.; Ye, Y.H.; Tan, R.X. New and cytotoxic anthraquinones from Pleospora sp. IFB-E006, an endophytic fungus in Imperata cylindrical. Planta. Med. 2005, 71, 1063–1065. [Google Scholar] [CrossRef]
  12. Alvi, K.A.; Rabenstein, J. Auxarthrol A and auxarthrol B: two new tetrahydoanthraquinones from Auxarthron umbrinum. J. Ind. Microbiol. Biotechnol. 2004, 31, 11–15. [Google Scholar] [CrossRef]
  13. Aly, A.H.; Edrada-Ebel, R.; Wray, V.; Müller, W.E.; Kozytska, S.; Hentschel, U.; Proksch, P.; Ebel, R. Bioactive metabolites from the endophytic fungus Ampelomyces sp. isolated from the medicinal plant Urospermum picroides. Phytochemistry 2008, 69, 1716–1725. [Google Scholar] [CrossRef] [PubMed]
  14. Uzor, P.F.; Ebrahim, W.; Osadebe, P.O.; Nwodo, J.N.; Okoye, F.B.; Muller, W.E.; Lin, W.; Liu, Z.; Proksch, P. Metabolites from Combretum dolichopetalum and its associated endophytic fungus Nigrospora oryzae-Evidence for a metabolic partnership. Fitoterapia 2015, 105, 147–150. [Google Scholar] [CrossRef]
  15. Klaiklay, S.; Rukachaisirikul, V.; Phongpaichit, S.; Pakawatchai, C.; Saithong, S.; Buatong, J.; Preedanon, S.; Sakayaroj, J. Anthraquinone derivatives from the mangrove-derived fungus Phomopsis sp. PSU-MA214. Phytochem. Lett. 2012, 5, 738–742. [Google Scholar] [CrossRef]
  16. Isaka, M.; Chinthanom, P.; Rachtawee, P.; Srichomthong, K.; Srikitikulchai, P.; Kongsaeree, P.; Prabpai, S. Cytotoxic hydroanthraquinones from the mangrove-derived fungus Paradictyoarthrinium diffractum BCC 8704. J. Antibiot (Tokyo) 2015, 68, 334–338. [Google Scholar] [CrossRef] [PubMed]
  17. Chen, B.; Shen, Q.; Zhu, X.; Lin, Y.C. The Anthraquinone Derivatives from the Fungus Alternaria sp. XZSBG-1 from the Saline Lake in Bange, Tibet, China. Molecules 2014, 19, 16529–16542. [Google Scholar] [CrossRef] [Green Version]
  18. Kelly, T.R.; Montury, M. A Regiochemically-controlled Synthesis of Altersolanol B. Tetrahedron. Lett. 1978, 45, 4309–4310. [Google Scholar] [CrossRef]
  19. Locatelli, M. Anthraquinones: Analytical Techniques as a Novel Tool to Investigate on the Triggering of Biological Targets. Curr. Drug. Targets. 2011, 12, 366–380. [Google Scholar] [CrossRef]
  20. Liu, P.; Wang, P.M.; Xu, J.Z. Assignment of NMR Data of Alterporriol I. Chem. Nat. Comp. 2017, 53, 653–657. [Google Scholar]
  21. Pretsch, A.; Proksch, P.; Debbab, A. New Anthraquinone Derivatives. U.S. Patent 0 129 927 Al, 24 May 2012. [Google Scholar]
  22. Bai, H.; Kong, W.W.; Shao, C.L.; Li, Y.; Liu, Y.Z.; Liu, M.; Guan, F.F.; Wang, C.Y. Zebrafish Embryo Toxicity Microscale Model for Ichthyotoxicity Evaluation of Marine Natural Products. Mar. Biotechnol. (NY) 2016, 18, 264–270. [Google Scholar] [CrossRef] [PubMed]
  23. Mosmann, T. Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays. J. Immunol. Meth. 1983, 65, 55–63. [Google Scholar] [CrossRef]
  24. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; Mahon, J.M.; Vistica, D.; Warren, J.T.; Bokesch, H.; Kenney, S.; Boyd, M.R. New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening. J. Natl. Cancer. Inst. 1990, 82, 1107–1112. [Google Scholar] [CrossRef]
  25. Yu, G.H.; Wu, G.W.; Sun, Z.C.; Zhang, X.M.; Che, Q.; Gu, Q.Q.; Zhu, T.J.; Li, D.H.; Zhang, G.J. Cytotoxic Tetrahydroxanthone Dimers from the Mangrove-Associated Fungus Aspergillus versicolor HDN1009. Mar. Drugs 2018, 16, 335. [Google Scholar] [CrossRef] [PubMed]
  26. Du, L.; Zhu, T.J.; Liu, H.B.; Fang, Y.C.; Zhu, W.M.; Gu, Q.Q. Cytotoxic polyketides from a marine-derived fungus, Aspergillus glaucus. J. Nat. Prod. 2008, 71, 1837–1842. [Google Scholar] [CrossRef] [PubMed]
  27. Xu, Z.; Liu, R.N.; Guan, H.S. Dual-target inhibitor screening against thrombin and factor Xa simultaneously by mass spectrometry. Anal. Chim. Acta 2017, 1–10. [Google Scholar] [CrossRef] [PubMed]
  28. Tang, J.; Wang, B.X.; Wu, T.; Wan, J.T.; Tu, Z.C.; Njire, M.; Wan, B.J.; Franzblauc, S.G.; Zhang, T.Y.; Lu, X.Y.; et al. Design, Synthesis, and Biological Evaluation of Pyrazolo [1,5-a] pyridine-3-carboxamides as Novel Antitubercular Agents. ACS Med. Chem. Lett. 2015, 6, 814–818. [Google Scholar] [CrossRef]
Figure 1. Structures of 1–7.
Figure 1. Structures of 1–7.
Marinedrugs 17 00334 g001
Figure 2. Key HMBC and 1H-1H COSY correlations of 15.
Figure 2. Key HMBC and 1H-1H COSY correlations of 15.
Marinedrugs 17 00334 g002
Figure 3. Key NOE correlations of 1–5.
Figure 3. Key NOE correlations of 1–5.
Marinedrugs 17 00334 g003
Figure 4. Comparison of the calculated and experimental ECD spectra of 1–2, auxarthrols D–E.
Figure 4. Comparison of the calculated and experimental ECD spectra of 1–2, auxarthrols D–E.
Marinedrugs 17 00334 g004
Figure 5. Comparison of the calculated and experimental ECD spectra of 34, auxarthrols F–G.
Figure 5. Comparison of the calculated and experimental ECD spectra of 34, auxarthrols F–G.
Marinedrugs 17 00334 g005
Figure 6. Comparison of the calculated and experimental ECD spectra of 5, auxarthrol H.
Figure 6. Comparison of the calculated and experimental ECD spectra of 5, auxarthrol H.
Marinedrugs 17 00334 g006
Table 1. 1H NMR data of compounds 15 (500 MHz, TMS, δ ppm, J in Hz).
Table 1. 1H NMR data of compounds 15 (500 MHz, TMS, δ ppm, J in Hz).
No.1 a2 a2 b3 a4 a5 a
11.86, m1.92, d (14.6);
1.83, d (14.6)
1.92, d (14.6);
1.83, d (14.6)
1.82, d (14.2);
1.75, d (14.2)
2.24, d (14.8);
1.74, d (14.8)
2.35, dd (15.5);
2.31, dd (15.5)
33.61, dd (5.7, 3.1)3.57, d (3.0)3.57, m3.46, t (3.0)3.61, d (3.6)3.46, d (3.7)
44.22, dd (4.5, 3.1)4.43, d (3.0)4.43, t (3.5)4.39, dd (3.0, 9.7)4.69, d (3.6)4.57, d (3.7)
66.79, d (2.4)6.35, d (2.5)6.35, d (2.5)6.34, d (2.4)6.82, d (2.5)6.42, d (2.4)
86.83, d (2.4)6.64, d (2.5)6.64, m6.67, d (2.4)6.96, d (2.5)6.67, dd (2.4, 1.2)
9 4.73, s4.73, d (9.5)4.52, d (8.7) 4.83, d (1.2)
1a3.36, (6.0, 1.5)
4a 2.87, d (9.7)
113.87, s3.80, s3.80, s3.81, s3.88, s3.82, s
121.14, s1.20, s1.20, s1.19, s1.27, s1.21, s
OH-24.28, s5.69, s5.69, s5.44, s6.24, s
OH-34.43, d (5.7) 5.50, d (5.3)4.81, d (3.0)4.91, s
OH-45.01, d (4.5) 4.52, d (3.5)4.57, d (3.0)4.96, s
OH-4a6.46, m5.56, s5.57, s
OH-512.44, s11.97, s11.97, s12.37, s11.15, s12.19, s
OH-1a 5.29, s5.29, s4.91, s6.97, s
OH-9 5.30, d (9.5)5.46, d (8.7)
a in DMSO; b in CDCl3.
Table 2. 13C NMR data of compounds 17 (125 MHz, DMSO, TMS, δ ppm).
Table 2. 13C NMR data of compounds 17 (125 MHz, DMSO, TMS, δ ppm).
No.12345
134.2, CH234.3, CH238.7, CH230.7, CH242.4, CH2
272.3, C73.5, C73.2, C73.6, C70.3, C
373.7, CH76.9, CH75.2, CH75.7, CH72.9, CH
471.3, CH64.6, CH66.1, CH63.5, CH65.2, CH
5166.1, C164.8, C163.8, C163.6, C164.9, C
6106.1, CH99.7, CH99.5, CH107.2, CH100.1, CH
7166.3, C166.4, C166.3, C165.7, C166.8, C
8105.0, CH106.2, CH105.8, CH106.4, CH106.6, CH
9197.3, C70.0, CH73.9, CH190.6, C68.6, CH
10200.1, C202.4, C206.0, C194.4, C196.6, C
1a48.0, CH79.3, C78.5, C80.5, C64.8, C
4a78.2, C78.1, C53.3, CH72.1, C63.3, C
9a137.6, C148.4, C149.0, C134.5, C145.9, C
10a110.1, C108.6, C110.8, C110.0, C107.1, C
1156.7, CH356.1, CH356.1, CH356.7, CH356.2, CH3
1223.1, CH327.6, CH327.8, CH327.6, CH326.1, CH3
Table 3. Cytotoxic effect of 1 and 3 against eleven human cancer cell lines.
Table 3. Cytotoxic effect of 1 and 3 against eleven human cancer cell lines.
Comp.IC50 (μM)
HL-60HelaHCT-116MGC-803HO8910MDA-MB-231SH-SY5YPC-3BEL-7402K562L-02
17.5>50.014.521.8>50.019.122.921.916.6>50.0>50.0
34.510.77.817.718.710.117.220.021.316.522.2
Dox a0.10.60.20.20.40.20.11.00.40.30.4
a Dox stands for doxorubicin hydrochloride, which was used as a positive control.
Table 4. Antimicrobial effect of 17 on seven microorganisms.
Table 4. Antimicrobial effect of 17 on seven microorganisms.
Comp.MIC (μM)
Mycobacterium PhleiProteus SpeciesBacillus subtilisCandida albicansVibrio ParahemolyticusEscherichia coliPseudomonas aeruginosa
125.050.0100>20050.010050.0
2>200>200>200>200>200>200>200
3200200200>200>200>200200
450.025.025.0200100>200100
5>200>200>200>200>200>200>200
625.050.025.0>20025.0>20025.0
725.010025.0>20025.0>20012.5
Positive Control3.12 a1.56 a0.781 a1.56 b0.781 a0.391 a1.56 a
a Ciprofloxacin used as a positive control for bacteria; b Nystatin used as a positive control for Candida albicans.
Table 5. Anticoagulant activity of 17.
Table 5. Anticoagulant activity of 17.
Comp.1234567Argatroban b
Inhibition ratio a12.519.914.447.827.351.519.365.0
a Data are expressed as inhibition ratio values (%); b Argatroban was used as a positive control.
Table 6. Antitubercular activity of 17 against AlRa.
Table 6. Antitubercular activity of 17 against AlRa.
Comp.1234567Rifampin b
MIC a>20.0>20.0>20.0>20.0>20.0>20.020.01.0
a Data are expressed as MIC values (μg/mL); b Rifampin was used as a positive control.

Share and Cite

MDPI and ACS Style

Ge, X.; Sun, C.; Feng, Y.; Wang, L.; Peng, J.; Che, Q.; Gu, Q.; Zhu, T.; Li, D.; Zhang, G. Anthraquinone Derivatives from a Marine-Derived Fungus Sporendonema casei HDN16-802. Mar. Drugs 2019, 17, 334. https://doi.org/10.3390/md17060334

AMA Style

Ge X, Sun C, Feng Y, Wang L, Peng J, Che Q, Gu Q, Zhu T, Li D, Zhang G. Anthraquinone Derivatives from a Marine-Derived Fungus Sporendonema casei HDN16-802. Marine Drugs. 2019; 17(6):334. https://doi.org/10.3390/md17060334

Chicago/Turabian Style

Ge, Xueping, Chunxiao Sun, Yanyan Feng, Lingzhi Wang, Jixing Peng, Qian Che, Qianqun Gu, Tianjiao Zhu, Dehai Li, and Guojian Zhang. 2019. "Anthraquinone Derivatives from a Marine-Derived Fungus Sporendonema casei HDN16-802" Marine Drugs 17, no. 6: 334. https://doi.org/10.3390/md17060334

APA Style

Ge, X., Sun, C., Feng, Y., Wang, L., Peng, J., Che, Q., Gu, Q., Zhu, T., Li, D., & Zhang, G. (2019). Anthraquinone Derivatives from a Marine-Derived Fungus Sporendonema casei HDN16-802. Marine Drugs, 17(6), 334. https://doi.org/10.3390/md17060334

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop